SPRO Spero Therapeutics, Inc.
Healthcare$2.76+2.60%ClosedMarket Cap: $159.8M
As of 2026-05-25
Valuation
P/E (TTM)
18.03
PEG
0.16
P/B
2.99
P/S
2.92
EV/EBITDA
7.52
DCF Value
$-30.48
FCF Yield
4.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
24.7%
Net Margin
27.8%
ROE
35.6%
ROA
25.8%
ROIC
23.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $258.0K | 100.0% | $-7.5M | $-7.2M | $— | — |
| Q4 null | $39.7M | 100.0% | $31.4M | $31.5M | $— | — |
| FY null | $59.6M | 100.0% | $-24.0K | $8.6M | $— | — |
| Q3 null | $3.0M | 100.0% | $-7.9M | $-7.4M | $— | — |
| Q2 null | $11.8M | 100.0% | $-2.4M | $-1.7M | $— | — |
| Q1 null | $5.9M | -131.6% | $-14.7M | $-13.9M | $— | — |
| Q4 null | $15.0M | -529.0% | $-21.7M | $-20.9M | $— | — |
| FY null | $48.0M | -101.7% | $-73.4M | $-68.6M | $— | — |
| Q3 null | $13.5M | 100.0% | $-18.6M | $-17.1M | $— | — |
| Q2 null | $10.2M | -132.7% | $-19.1M | $-17.9M | $— | — |
| Q1 null | $4.2M | 100.0% | $-14.0M | $-12.7M | $— | — |
| Q4 2023 | $73.5M | 32.8% | $50.5M | $51.2M | $0.96 | — |